165 related articles for article (PubMed ID: 38515178)
1. Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition.
Deben C; Boullosa LF; Fortes FR; De La Hoz EC; Le Compte M; Seghers S; Peeters M; Vanlanduit S; Lin A; Dijkstra KK; Van Schil P; Hendriks JMH; Prenen H; Roeyen G; Lardon F; Smits E
J Exp Clin Cancer Res; 2024 Mar; 43(1):88. PubMed ID: 38515178
[TBL] [Abstract][Full Text] [Related]
2. Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers.
Freire Boullosa L; Van Loenhout J; Flieswasser T; Hermans C; Merlin C; Lau HW; Marcq E; Verschuuren M; De Vos WH; Lardon F; Smits ELJ; Deben C
Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978917
[TBL] [Abstract][Full Text] [Related]
3. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells.
Li H; Hu J; Wu S; Wang L; Cao X; Zhang X; Dai B; Cao M; Shao R; Zhang R; Majidi M; Ji L; Heymach JV; Wang M; Pan S; Minna J; Mehran RJ; Swisher SG; Roth JA; Fang B
Oncotarget; 2016 Jan; 7(3):3548-58. PubMed ID: 26657290
[TBL] [Abstract][Full Text] [Related]
4. KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer.
Dai B; Yoo SY; Bartholomeusz G; Graham RA; Majidi M; Yan S; Meng J; Ji L; Coombes K; Minna JD; Fang B; Roth JA
Cancer Res; 2013 Sep; 73(17):5532-43. PubMed ID: 23824739
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
[TBL] [Abstract][Full Text] [Related]
6. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer.
Freire Boullosa L; Van Loenhout J; Flieswasser T; De Waele J; Hermans C; Lambrechts H; Cuypers B; Laukens K; Bartholomeus E; Siozopoulou V; De Vos WH; Peeters M; Smits ELJ; Deben C
Redox Biol; 2021 Jun; 42():101949. PubMed ID: 33812801
[TBL] [Abstract][Full Text] [Related]
7. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
8. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system.
Schuth S; Le Blanc S; Krieger TG; Jabs J; Schenk M; Giese NA; Büchler MW; Eils R; Conrad C; Strobel O
J Exp Clin Cancer Res; 2022 Oct; 41(1):312. PubMed ID: 36273171
[TBL] [Abstract][Full Text] [Related]
9. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin.
Xiaobo C; Majidi M; Feng M; Shao R; Wang J; Zhao Y; Baladandayuthapani V; Song J; Fang B; Ji L; Mehran R; Roth JA
Sci Rep; 2016 Nov; 6():35741. PubMed ID: 27845352
[TBL] [Abstract][Full Text] [Related]
10. PDX-derived organoids model in vivo drug response and secrete biomarkers.
Huang L; Bockorny B; Paul I; Akshinthala D; Frappart PO; Gandarilla O; Bose A; Sanchez-Gonzalez V; Rouse EE; Lehoux SD; Pandell N; Lim CM; Clohessy JG; Grossman J; Gonzalez R; Del Pino SP; Daaboul G; Sawhney MS; Freedman SD; Kleger A; Cummings RD; Emili A; Muthuswamy LB; Hidalgo M; Muthuswamy SK
JCI Insight; 2020 Nov; 5(21):. PubMed ID: 32990680
[TBL] [Abstract][Full Text] [Related]
11. Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer.
Shi R; Radulovich N; Ng C; Liu N; Notsuda H; Cabanero M; Martins-Filho SN; Raghavan V; Li Q; Mer AS; Rosen JC; Li M; Wang YH; Tamblyn L; Pham NA; Haibe-Kains B; Liu G; Moghal N; Tsao MS
Clin Cancer Res; 2020 Mar; 26(5):1162-1174. PubMed ID: 31694835
[TBL] [Abstract][Full Text] [Related]
12. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
[TBL] [Abstract][Full Text] [Related]
13. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer.
Ponz-Sarvise M; Corbo V; Tiriac H; Engle DD; Frese KK; Oni TE; Hwang CI; Öhlund D; Chio IIC; Baker LA; Filippini D; Wright K; Bapiro TE; Huang P; Smith P; Yu KH; Jodrell DI; Park Y; Tuveson DA
Clin Cancer Res; 2019 Nov; 25(22):6742-6755. PubMed ID: 31492749
[TBL] [Abstract][Full Text] [Related]
14. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
Pan CH; Otsuka Y; Sridharan B; Woo M; Leiton CV; Babu S; Torrente Gonçalves M; Kawalerski RR; K Bai JD; Chang DK; Biankin AV; Scampavia L; Spicer T; Escobar-Hoyos LF; Shroyer KR
Mol Oncol; 2020 Aug; 14(8):1800-1816. PubMed ID: 32533886
[TBL] [Abstract][Full Text] [Related]
15. Eravacycline, an antibacterial drug, repurposed for pancreatic cancer therapy: insights from a molecular-based deep learning model.
Jabarin A; Shtar G; Feinshtein V; Mazuz E; Shapira B; Ben-Shabat S; Rokach L
Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38647152
[TBL] [Abstract][Full Text] [Related]
16. Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids.
Palzer J; Mues B; Goerg R; Aberle M; Rensen SS; Olde Damink SWM; Vaes RDW; Cramer T; Schmitz-Rode T; Neumann UP; Slabu I; Roeth AA
Int J Nanomedicine; 2021; 16():2965-2981. PubMed ID: 33935496
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo.
Fan C; Zheng W; Fu X; Li X; Wong YS; Chen T
Cell Death Dis; 2014 Apr; 5(4):e1191. PubMed ID: 24763048
[TBL] [Abstract][Full Text] [Related]
18. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
[TBL] [Abstract][Full Text] [Related]
19. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
Meng J; Dai B; Fang B; Bekele BN; Bornmann WG; Sun D; Peng Z; Herbst RS; Papadimitrakopoulou V; Minna JD; Peyton M; Roth JA
PLoS One; 2010 Nov; 5(11):e14124. PubMed ID: 21124782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
